Fig. 1. Pancreatic and exopancreatic actions of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide‐1 (GLP-1). *Evidence from preclinical studies.

J Obes Metab Syndr 2023;32:25~45 https://doi.org/10.7570/jomes22067

© JOMES